Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073957 · ClinicalTrials.gov registry record · Phase 2
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT00073957 is a Phase 2 study of Lymphoma that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 25 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00073957, a Phase 2 study of Lymphoma, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan and rituximab, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Combining yttrium Y 90 ibritumomab tiuxetan with rituximab may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining yttrium Y 90 Ibritumomab tiuxetan with rituximab in treating patients who have relapsed or refractory diffuse large B-cell non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL rituximab
- DRUG cytarabine
- DRUG liposomal cytarabine
- RADIATION yttrium Y 90 ibritumomab tiuxetan
Study Locations (2)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Vermont
- Fletcher Allen Health Care - Medical Center Campus - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2003-12 |
| Est. Completion | 2012-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073957
The ClinicalTrials.gov registry entry for NCT00073957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which rituximab is the first listed.
NCT00073957 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Vermont.
Frequently Asked Questions
What is clinical trial NCT00073957 about?
NCT00073957 is a clinical study titled "Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan and rituximab, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Combining yttrium Y 90 ibritumomab tiuxetan with rituximab may kill more canc...
What is the current status of trial NCT00073957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2003-12. Estimated completion is 2012-01-01.
What conditions does trial NCT00073957 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00073957?
The interventions under investigation include: rituximab (BIOLOGICAL), cytarabine (DRUG), liposomal cytarabine (DRUG), yttrium Y 90 ibritumomab tiuxetan (RADIATION).
Who is sponsoring clinical trial NCT00073957?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073957 being conducted?
This trial has 2 study locations across Massachusetts, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.